Enliven Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; filed May 14, 2024. Enliven is a clinical-stage oncology biotech developing small-molecule inhibitors. It has no approved products and generated no revenue.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $20.0 million | $11.9 million |
| General and administrative expense | $6.0 million | $4.5 million |
| Total operating expenses | $26.0 million | $16.4 million |
| Operating loss | $26.0 million | $16.4 million |
| Interest income; total other income | $3.3 million | $1.7 million |
| Net loss | $22.7 million | $14.7 million |
| Basic and diluted loss per share | $0.54 | $0.80 |
| Net cash used in operating activities | $23.4 million | $20.8 million |
Margins are not meaningful because the company has no revenue. Net loss per share declined despite a larger net loss, alongside a substantial increase in weighted-average shares.
- Liquidity at March 31: $149.2 million cash and cash equivalents plus $171.3 million marketable securities, totaling $320.5 million. Current assets were $337.2 million and current liabilities $25.0 million.
- Debt: No debt outstanding. Marketable securities were primarily U.S. Treasury securities; the company reported no credit or impairment losses.
- Cash flows: Investing activities used $17.9 million, mainly reflecting purchases of marketable securities net of maturities. Financing provided $90.3 million, principally from the March private placement.
- Balance sheet: Total assets were $342.8 million, total liabilities $25.1 million, and accumulated deficit $177.2 million.
Material changes versus Q1 2023
- Operating expenses increased $9.6 million, and net loss increased $8.0 million. R&D rose $8.1 million, mainly from clinical-trial and manufacturing costs and higher employee-related expenses; G&A rose $1.5 million.
- Interest income increased $1.6 million, attributed to higher interest rates and investment balances.
- Operating cash use increased $2.5 million. Cash, cash equivalents and restricted cash increased $49.0 million in Q1 2024, compared with a $216.6 million increase in Q1 2023, which included merger-related financing and cash acquired in the reverse recapitalization.
- On March 21, 2024, Enliven raised $90.0 million gross through a private placement of 5.36 million common shares and pre-funded warrants for 1.07 million shares. The warrants were unexercised at quarter-end. Shares outstanding rose to 46.78 million from 41.29 million at December 31, 2023.
Outlook, commentary and risks
- Management expects continued operating losses and negative operating cash flows as it advances its programs. No formal revenue or earnings guidance is provided. The filing says available cash, cash equivalents and marketable securities should fund planned needs for at least 12 months from issuance; a risk-factor discussion separately estimates funding into late 2026. These statements use different horizons and assumptions and should be reconciled.
- Enliven is advancing ELVN-001 (BCR-ABL) and ELVN-002 (HER2), with a third development candidate nominated and IND-enabling studies completed. The FDA cleared an additional Phase 1 ELVN-002 combination trial, and its first site was activated in Q1.
- After quarter-end, in April 2024, the company announced positive proof-of-concept data from the ELVN-001 Phase 1 trial. The filing cautions that preliminary clinical data may change as follow-up and verification continue.
- The company received formal notice in March that a $10 million asset-sale milestone had been achieved and received the cash in April. The $10 million CVR asset and matching liability remained on the March 31 balance sheet; the proceeds are to be distributed to CVR holders, net of permitted deductions.
- Key risks include early-stage clinical and regulatory uncertainty, dependence on ELVN-001 and ELVN-002, trial enrollment and competition, reliance on third-party research and manufacturing providers, potential supply disruption involving a China-based provider, and geopolitical or operational risks at planned Israeli trial sites. The Boulder facility sublease expires in December 2024; the company is assessing alternative space.
- The company reported no current material litigation, no off-balance-sheet arrangements, and effective disclosure controls as of March 31, 2024.
Important facts for investors to verify
- Reconcile the stated cash runway estimates—at least 12 months from filing versus into late 2026—and review the operating assumptions behind them.
- Review full ELVN-001 proof-of-concept results and subsequent clinical updates, including the distinction between preliminary and confirmed data.
- Track ELVN-002 trial progress, enrollment, combination-drug supply and development costs, as well as the third candidate’s development timeline.
- Assess quarterly cash burn against the $320.5 million liquidity balance and expected clinical, manufacturing and public-company costs.
- Monitor dilution from the private placement, outstanding pre-funded warrants, equity awards and any future financing; the company also has an unused at-the-market sales agreement of up to $200 million.
- Confirm distribution of the $10 million milestone proceeds to CVR holders and monitor progress on the facility transition before the lease expires.